Pamela D Winterberg1,2, Jennifer M Robertson3, Michael S Kelleman4, Roshan P George5,3, Mandy L Ford3. 1. Division of Pediatric Nephrology, Department of Pediatrics, pdwinte@emory.edu. 2. Children's Healthcare of Atlanta, Atlanta, Georgia. 3. Emory Transplant Center, Department of Surgery, and. 4. Biostatistics Core, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia; and. 5. Division of Pediatric Nephrology, Department of Pediatrics.
Abstract
BACKGROUND: Uremic cardiomyopathy, characterized by left ventricular hypertrophy, diastolic dysfunction, and impaired myocardial strain, contributes to increased cardiovascular mortality in patients with CKD. Emerging evidence suggests a pathogenic role for T cells during chronic heart failure. METHODS: To determine whether T cells contribute to uremic cardiomyopathy pathogenesis, we modeled this condition by inducing CKD via 5/6th nephrectomy in mice. We used flow cytometry to assess expression of markers of T cell memory or activation by lymphocytes from CKD mice and controls, as well as lymphocyte capacity for cytokine production. Flow cytometry was also used to quantify immune cells isolated from heart tissue. To test effects of T cell depletion on cardiac function, we gave CKD mice anti-CD3 antibody injections to deplete T cells and compared heart function (assessed by echocardiography) with that of controls. Finally, we correlated T cell phenotypes with structural and functional measures on clinically acquired echocardiograms in children with CKD. RESULTS: Mice with CKD accumulated T cells bearing markers of memory differentiation (CD44hi) and activation (PD-1, KLRG1, OX40), as reported previously in human CKD. In addition, mice with CKD showed T cells infiltrating the heart. T cell depletion significantly improved both diastolic function and myocardial strain in CKD mice without altering hypertension or degree of renal dysfunction. In children with CKD, increasing frequency of T cells bearing activation markers PD-1 and/or CD57 was associated with worsening diastolic function on echocardiogram. CONCLUSIONS: CKD results in an accumulation of proinflammatory T cells that appears to contribute to myocardial dysfunction.
BACKGROUND: Uremic cardiomyopathy, characterized by left ventricular hypertrophy, diastolic dysfunction, and impaired myocardial strain, contributes to increased cardiovascular mortality in patients with CKD. Emerging evidence suggests a pathogenic role for T cells during chronic heart failure. METHODS: To determine whether T cells contribute to uremic cardiomyopathy pathogenesis, we modeled this condition by inducing CKD via 5/6th nephrectomy in mice. We used flow cytometry to assess expression of markers of T cell memory or activation by lymphocytes from CKD mice and controls, as well as lymphocyte capacity for cytokine production. Flow cytometry was also used to quantify immune cells isolated from heart tissue. To test effects of T cell depletion on cardiac function, we gave CKD mice anti-CD3 antibody injections to deplete T cells and compared heart function (assessed by echocardiography) with that of controls. Finally, we correlated T cell phenotypes with structural and functional measures on clinically acquired echocardiograms in children with CKD. RESULTS: Mice with CKD accumulated T cells bearing markers of memory differentiation (CD44hi) and activation (PD-1, KLRG1, OX40), as reported previously in human CKD. In addition, mice with CKD showed T cells infiltrating the heart. T cell depletion significantly improved both diastolic function and myocardial strain in CKD mice without altering hypertension or degree of renal dysfunction. In children with CKD, increasing frequency of T cells bearing activation markers PD-1 and/or CD57 was associated with worsening diastolic function on echocardiogram. CONCLUSIONS: CKD results in an accumulation of proinflammatory T cells that appears to contribute to myocardial dysfunction.
Authors: Jaap W Groothoff; Mariken P Gruppen; Martin Offringa; Jeroen Hutten; Marc R Lilien; Nicole J Van De Kar; Eric D Wolff; Jean Claude Davin; Hugo S A Heymans Journal: Kidney Int Date: 2002-02 Impact factor: 10.612
Authors: M Espinoza; A Aguilera; M Auxiliadora Bajo; R Codoceo; E Caravaca; A Cirugeda; G del Peso; C Hevia; R Selgas Journal: Adv Perit Dial Date: 1999
Authors: H Nishimura; T Okazaki; Y Tanaka; K Nakatani; M Hara; A Matsumori; S Sasayama; A Mizoguchi; H Hiai; N Minato; T Honjo Journal: Science Date: 2001-01-12 Impact factor: 47.728
Authors: Jason M Brenchley; Nitin J Karandikar; Michael R Betts; David R Ambrozak; Brenna J Hill; Laura E Crotty; Joseph P Casazza; Janaki Kuruppu; Stephen A Migueles; Mark Connors; Mario Roederer; Daniel C Douek; Richard A Koup Journal: Blood Date: 2002-11-14 Impact factor: 22.113
Authors: D M Sze; G Giesajtis; R D Brown; M Raitakari; J Gibson; J Ho; A G Baxter; B Fazekas de St Groth; A Basten; D E Joshua Journal: Blood Date: 2001-11-01 Impact factor: 22.113
Authors: Nisha Bansal; Leila Zelnick; Alan Go; Amanda Anderson; Robert Christenson; Rajat Deo; Christopher Defilippi; James Lash; Jiang He; Bonnie Ky; Stephen Seliger; Elsayed Soliman; Michael Shlipak Journal: J Am Heart Assoc Date: 2019-10-24 Impact factor: 5.501
Authors: M A Mawhin; R G Bright; J D Fourre; E I Vloumidi; J Tomlinson; A Sardini; C D Pusey; K J Woollard Journal: BMC Nephrol Date: 2022-01-28 Impact factor: 2.388